Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Drug development involves a deep understanding of the mechanisms of action and possible side effects of each drug, and sometimes results in the identification of new and unexpected uses for drugs, termed as drug repurposing. Both in case of serendipitous observations and systematic mechanistic explorations, confirmation of new indications for a drug requires hypothesis building around relevant drug-related data, such as molecular targets involved, and patient and cellular responses. These datasets are available in public repositories, but apart from sifting through the sheer amount of data imposing computational bottleneck, a major challenge is the difficulty in selecting which databases to use from an increasingly large number of available databases. The database selection is made harder by the lack of an overview of the types of data offered in each database. In order to alleviate these problems and to guide the end user through the drug repurposing efforts, we provide here a survey of 102 of the most promising and drug-relevant databases reported to date. We summarize the target coverage and types of data available in each database and provide several examples of how multi-database exploration can facilitate drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077 · cited 5×
“Among pathway databases, KEGG [85] is one of the most comprehensive and nonredundant database (0.”
MethodInfluentialKEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“[10, 23]), including: DepMap [26], cBioPortal [27], Probes & Drugs portal [28], DrugComb [29], DrugTargetCommons(DTC) [30], DrugTargetProfiler (DTP) [31], IDAAPM [32], PharmacoDB [33] and DisGeNet [34].”
MethodRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 2×
“Addition of PPI data from STRING [72] D ow nloaded from https://academ ic.oup.com /bib/advance-article-abstract/doi/10.1093/bib/bbaa003/5735620 by guest on 11 M arch 2020 generated a new method, termed HNMDRP, that outperformed several state-of-the-art machine learning-based methods in correctly correlating responses…”
MethodInfluentialNCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865 · cited 4×
“Hence, we assigned ‘Pathways’ as primary subcategory for KEGG, which is listed under the main category ‘biomolecular’, as shown in Table 2.”
BackgroundInfluential
Research works printed but not linked: 1
- Lotfi Shahreza, 2018, A review of network-based approaches to drug repositioning, Brief Bioinform, 19, 878, 10.1093/bib/bbx017 · DOI · Paper page
Cited by
Use of molecular docking computational tools in drug discovery
(2021) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2021.01.004 · Cited by 621
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“27,28 More often, these techniques are synergistically utilized.”
MethodArtificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M., & Aittokallio, T. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 222
“Databases and other resources supporting insilico drug repurposing, such as Drug Repurposing Hub [9] and RepurposeDB [10], have also been recently surveyed [11].”
BackgroundMethodSelf-citationDeep learning for drug repurposing: Methods, databases, and applications
Pan, X., Lin, X., Cao, D., Zeng, X., Yu, P. S., He, L., Nussinov, R., & Cheng, F. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1597 · Cited by 188
“’s study.[22] Actually, deep learning is well suited to integrate heterogeneous data sources.”
BackgroundMethodA review on drug repurposing applicable to COVID-19
Dotolo, S., Marabotti, A., Facchiano, A., & Tagliaferri, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa288 · Cited by 181
A review of biomedical datasets relating to drug discovery: a knowledge graph perspective
Bonner, S., Barrett, I. P., Ye, C., Swiers, R., Engkvist, O., Bender, A., Hoyt, C. T., & Hamilton, W. L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac404 · Cited by 196
Recent advances in metabolomics analysis for early drug development
Alarcon-Barrera, J. C., Kostidis, S., Ondo-Mendez, A., & Giera, M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.018 · Cited by 138
Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace
Singh, N., Chaput, L., & Villoutreix, B. O. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa034 · Cited by 136
“Three very recent reviews on chemistry databases [42, 142] and Omics and target databases [143] have just been reported and cover all the major databases that most users will need to embark in a virtual screening project.”
BackgroundComputational drug repurposing: approaches, evaluation of in silico resources and case studies
Tanoli, Z., Fernández‐Torras, A., Özcan, U. O., Kushnir, A., Nader, K. M., Gadiya, Y., Fiorenza, L., Ianevski, A., Vähä-Koskela, M. J. V., Miihkinen, M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01164-x · Cited by 122
Self-citationAhmed, F., Soomro, A. M., Salih, A. R. C., Samantasinghar, A., Asif, A., Kang, I. S., & Choi, K. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113350 · Cited by 99
“Moreover, survey targeting the drug repurposing have also been performed [15,16] and these include comments and opinion focusing the drug design [17] and development process [18].”
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 88
Metapath-aggregated heterogeneous graph neural network for drug–target interaction prediction
Li, M., Cai, X., Xu, S., & Ji, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac578 · Cited by 88
Liu, J., Guan, S., Zou, Q., Wu, H., Tiwari, P., & Ding, Y. (2023) · Knowledge-Based Systems · doi:10.1016/j.knosys.2023.111329 · Cited by 83
Computational analyses of mechanism of action (MoA): data, methods and integration
Trapotsi, M.-A., Hosseini-Gerami, L., & Bender, A. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00069a · Cited by 71
“43 High-throughput screening (HTS) technologies have been developed which enable rapid and cheap screening of thousands of molecules against panels of compound targets, 21 thus large-scale databases of bioactivity measurements are available.”
BackgroundAhmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., Memon, F. H., & Choi, K. H. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28693 · Cited by 69
Artificial intelligence for drug repurposing against infectious diseases
Singh, A. (2024) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2024.100071 · Cited by 74
Yes SIR! On the structure–inactivity relationships in drug discovery
López‐López, E., Gortari, E. F., & Medina‐Franco, J. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.005 · Cited by 60
Validation guidelines for drug-target prediction methods
Tanoli, Z., Schulman, A., & Aittokallio, T. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2430955 · Cited by 60
Self-citationDrug Repurposing: A Leading Strategy for New Threats and Targets
Mishra, A. S., Vasanthan, M., & Malliappan, S. P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00361 · Cited by 61
DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features
Wang, Y., Aldahdooh, J., Hu, Y., Yang, H., Vähä-Koskela, M. J. V., Tang, J. P., & Tanoli, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-24980-2 · Cited by 58
Self-citationA Systems Approach to Brain Tumor Treatment
Park, J. H., de Lomana, A. L. G., Marzese, D. M., Juarez, T., Feroze, A. H., Hothi, P., Cobbs, C., Patel, A. P., Kesari, S., Huang, S., et al. (2021) · Cancers · doi:10.3390/cancers13133152 · Cited by 54
Heterogeneous graph inference with matrix completion for computational drug repositioning
Yang, M., Huang, L., Xu, Y., Lu, C., & Wang, J. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa1024 · Cited by 45
Machine learning for drug repositioning: Recent advances and challenges
Cai, L., Chu, J., Xu, J., Meng, Y., Lu, C., Tang, X., Wang, G., Tian, G., & Yang, J. (2023) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2023.100042 · Cited by 48
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
Zhu, S., Bai, Q., Li, L., & Xu, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.057 · Cited by 46
“Tanoli et al. [40] presented an overview of 102 data-base resources available for drug repositioning in four categories, namely drug-target interaction, disease, chemical, and biomolecular databases, and showed their applications for drug repositioning.”
BackgroundThe OREGANO knowledge graph for computational drug repurposing
Boudin, M., Diallo, G., Drancé, M., & Mougin, F. (2023) · Scientific Data · doi:10.1038/s41597-023-02757-0 · Cited by 60
“Numerous resources describe portions of this body of knowledge, many of them available online 7 .”
BackgroundReconciling multiple connectivity scores for drug repurposing
Samart, K., Tuyishime, P., Krishnan, A., & Ravi, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab161 · Cited by 45
“Also essential to this growing infrastructure are living surveys of methods and databases [6] as well as unified definition and notation systems like the one presented in this article.”
BackgroundMethodXia, X., Zhu, C., Zhong, F., & Liu, L. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad411 · Cited by 47
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“206 As starting point, we found the Drug Repurposing Hub, currently annotating about 6800 compounds with preclinical and clinical data, to be an effective tool to guide decision-making.”
BackgroundSaifi, I., Bhat, B. A., Hamdani, S. S., Bhat, U. Y., Lobato-Tapia, C. A., Mir, M. A., Dar, T. U. H., & Ganie, S. A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2234039 · Cited by 43
“For more information on the tools published before 2021, we recommend reading review articles by Elizabeth and Prashanth (Sam & Athri, 2019), as well as Ziaurrehman et al. (Tanoli et al., 2021) (Table 9).”
BackgroundMethodVirtual Combinatorial Chemistry and Pharmacological Screening: A Short Guide to Drug Design
Suay‐García, B., Bueso-Bordils, J. I., Falcó, A., Antón-Fos, G. M., & Aleman, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031620 · Cited by 40
“The number of chemical databases available for VS has increased exponentially in the last few years as the advances in computational methods have vastly increased the information output [70].”
BackgroundUsing BERT to identify drug-target interactions from whole PubMed
Aldahdooh, J., Vähä-Koskela, M. J. V., Tang, J. P., & Tanoli, Z. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04768-x · Cited by 42
Self-citationDong, F., He, K., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X., Zhang, N., Li, B.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114818 · Cited by 41
Combining repurposed drugs to treat colorectal cancer
Duarte, D., & Vale, N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.012 · Cited by 32
Yang, Z., Yang, Z., Zhao, Y., Yin, M., Lü, A., Chen, X., Liu, S., Hou, T., & Cao, D. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab017 · Cited by 30
Databases of ligand-binding pockets and protein-ligand interactions
Carpenter, K. A., & Altman, R. B. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.03.015 · Cited by 36
Machine Learning and Artificial Intelligence in Drug Repurposing—Challenges and Perspectives
Anokian, E., Bernett, J., Freeman, A., List, M., Santamaría, L. P., Tanoli, Z., & Bonnin, S. (2024) · Drug repurposing · doi:10.58647/drugrepo.24.1.0004 · Cited by 34
“25 In tandem with web-based resources, various prediction methods for drug repurposing have been introduced.”
BackgroundSelf-citationIanevski, A., Kushnir, A., Nader, K. M., Miihkinen, M., Xhaard, H., Aittokallio, T. A., & Tanoli, Z. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae328 · Cited by 28
“Over the recent years, various computational resources have been developed to support DR efforts, including DrugRepo [7], Drug Repurposing Hub [8], repoDB [9] and RepurposeDB [10], alongside hundreds of other web-based databases that can directly or indirectly support DR [11].”
BackgroundSelf-citationChoi, H. M., Moon, S. Y., Yang, H.-I., & Kim, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041737 · Cited by 32
“Repositioned drugs are being discovered through specific pharmacological insights or experimental screening platforms [5,6].”
BackgroundDrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses
Rajput, A., Kumar, A., Megha, K., Thakur, A., & Kumar, M. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa421 · Cited by 24
Drug-Repositioning Approaches Based on Medical and Life Science Databases
Zamami, Y., Hamano, H., Niimura, T., Aizawa, F., Yagi, K., Goda, M., Izawa‐Ishizawa, Y., & Ishizawa, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752174 · Cited by 24
“The advent of several promising and drug-relevant databases has led to the exploration of a wide range of target coverages and data types (Tanoli et al., 2021).”
BackgroundEskandarzade, N., Ghorbani, A., Samarfard, S., Díaz, J., Guzzi, P. H., Fariborzi, N., Tahmasebi, A., & Izadpanah, K. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105575 · Cited by 22
LigAdvisor: a versatile and user-friendly web-platform for drug design
Pinzi, L., Tinivella, A., Gagliardelli, L., Beneventano, D., & Rastelli, G. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab385 · Cited by 22
“Currently, other databases specifically focussing on drugs, their therapeutic indications, bioactivity data and drug–target interactions have been reported to facilitate drug repurposing (8,9,11,12) (Supplementary Table S1).”
TBGA: a large-scale Gene-Disease Association dataset for Biomedical Relation Extraction
Marchesin, S., & Silvello, G. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04646-6 · Cited by 25
“We chose Dis-GeNET as source database since it is one of the most comprehensive databases for GDAs [31], integrating several expert-curated resources, such as UniProt [1], CTD [3], and Psy-GeNET [32].”
MethodGholizadeh, E., Karbalaei, R., Khaleghian, A., Salimi, M., Gilany, K., Soliymani, R., Tanoli, Z., Rezadoost, H., Baumann, M., Jafari, M., et al. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.120.000210 · Cited by 19
Self-citationCREAMMIST: an integrative probabilistic database for cancer drug response prediction
Yingtaweesittikul, H., Wu, J., Mongia, A., Peres, R., Ko, K. K. K., Nagarajan, N., & Suphavilai, C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac911 · Cited by 21
“Diverse strategies to make use of the existing cancer drug screening data are needed not only for biomarker identification but also for building knowledge to guide drug repropositioning (11,49).”
BackgroundTanoli, Z., Aldahdooh, J., Alam, F., Wang, Y., Seemab, U., Fratelli, M., Pavliš, P., Hajdúch, M., Biétrix, F., Gribbon, P. M., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab350 · Cited by 18
Self-citationLiu, Y., Liu, Y., Fan, R., Kehriman, N., Zhang, X., Zhao, B., & Huang, L. (2023) · European journal of medical research · doi:10.1186/s40001-023-01048-z · Cited by 17
“Other than approaches that are primarily focused on omics- or ligand docking, adverse event (AE)-based drug repurposing is a novel strategy [3].”
BackgroundDrug Repurposing: Insights into Current Advances and Future Applications
Bhatia, T., & Sharma, S. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673266470231023110841 · Cited by 19
Quantitative systems pharmacology of the eye: Tools and data for ocular QSP
Kuepfer, L., Fuellen, G., & Stahnke, T. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12918 · Cited by 18
Hu, S., Chen, S., Li, Z., Wang, Y., & Wang, Y. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.47555 · Cited by 15
“In addition, multi-database exploration could facilitate mechanism understanding and drug repurposing [14].”
BackgroundEmon, M. A., Domingo‐Fernándéz, D., Hoyt, C. T., & Hofmann‐Apitius, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03568-5 · Cited by 13
“…repositioning methods have recently become popular due to the increased availability of drug-related -omics data through sources like CMap (Connect-ivity Map [4]) and LINCS (Library of Integrated Network-Based Cellular Signatures [5]) (see Tanoli et al. [6] for a review on databases and methods).”
BackgroundFrom Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases
Hussain, M. S., Mir, P. A., Kumar, N., Mohi-ud-din, R., Wali, A. F., Mir, R. H., Talath, S., Sridhar, S. B., Shareef, J., Goud, M., et al. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1070716 · Cited by 23
“Safeguarding patient confdentiality and guaranteeing the conscientious use of delicate health data are fundamental ethical considerations [189].”
Fawzy, M. P., Nafie, M. S., Nabih, N. W., Diab, M. K., Babker, A. M. A., Mohamed, H., Hassan, H. A. F. M., & Fahmy, S. A. (2026) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2026.100168 · Cited by 17
A review of SARS-CoV-2 drug repurposing: databases and machine learning models
Elkashlan, M., Ahmad, R. M., Hajar, M., Jasmi, F. A., Corchado, J. M., Nasarudin, N. A., & Mohamad, M. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182465 · Cited by 16
Drug Metabolism and Pharmacokinetics
Rudrapal, M. (2023) · Pharmaceutical science. · doi:10.5772/intechopen.111605 · Cited by 13
The Role of Bioinformatics in Drug Discovery: A Comprehensive Overview
Somda, D., Kpordze, S. W., Jerpkorir, M., Mahora, M. C., Ndung’u, J., Kamau, S. W., Arthur, V., & Elbasyouni, A. (2023) · Pharmaceutical science. · doi:10.5772/intechopen.113712 · Cited by 11
Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing
Makeeva, V. S., Dyrkheeva, N. S., Lavrik, O. I., Zakian, S. M., & Malakhova, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316798 · Cited by 13
Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
Santos, J., Costa, A. C., Dias, T. R., Satari, S., Silva, M. P. C. E., da Costa, R. M. G., & Medeiros, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111084 · Cited by 13
Data-driven strategies for drug repurposing: insights, recommendations, and case studies
Savander, S., Curabaz, N. N., Abbasi, A. M., Khan, A., Saeed, K., & Tanoli, Z. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf625 · Cited by 10
“As summarized in previous reviews [14, 15], dozens of publicly available DTI resources now exist, though their quality, coverage, and data curation standards vary significantly.”
Self-citationMiRAGE: mining relationships for advanced generative evaluation in drug repositioning
Aragh, A. H., Givehchian, P., Amirani, R. M., Masumshah, R., & Eslahchi, C. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae337 · Cited by 10
“To address these challenges, the pursuit of new indications for existing drugs, a concept known as drug repositioning, has emerged as an economically feasible and time-saving strategy [3, 4].”
Agastheeswaramoorthy, K., & Sevilimedu, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.25.311142 · Cited by 11
“The larger the number of data features and sample numbers available for generating such a comprehensive map, the stronger the likelihood of identifying a drug repurposing candidate(12,13).”
BackgroundData-driven strategies for drug repurposing: insights, recommendations, and case studies
Savander, S., Curabaz, N. N., Abbasi, A. M., Khan, A., Saeed, K., & Tanoli, Z. (2025) · doi:10.1101/2025.08.18.670836 · Cited by 10
Self-citationAlqahtani, S. M. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105772 · Cited by 10
Explainable Drug Repurposing Approach From Biased Random Walks
Castiglione, F., Nardini, C., Onofri, E., Pedicini, M., & Tieri, P. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3191392 · Cited by 12
“Such approaches leverage on many different large datasets developed during the last decades, when the global knowledge on drugs and diseases properties has considerably increased [15].”
BackgroundContrastive Meta-Learning for Drug-Target Binding Affinity Prediction
Li, M., Xu, S., Cai, X., Zhang, Z., & Ji, H. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995372 · Cited by 11
“Drug-target binding affinity (DTA) prediction is critical in drug discovery, drug repositioning, and side-effect prediction [1]–[3].”
BackgroundZhang, S., Zhang, R., Zheng, L., Liu, Y., Fan, Q., Liu, Y., Ning, X., Zhang, Y., Chen, Y., & Liu, H. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11247-x · Cited by 10
“5, Life science databases include chemical databases, biomolecule databases, drug–target interaction databases [90], protein interaction information databases, and disease association databases.”
Data curation in cheminformatics: importance and implementation
Esaki, T., & Ikeda, K. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01174-w · Cited by 14
“This limitation is a challenge when data are aggregated [26, 77–79], and significant effort may be required to analyze the text or refer to original sources to understand the conditions under which each data point was obtained.”
A review on drug repurposing applicable to obesity
Chen, F., Jing, K., Zhang, Z., & Liu, X. (2024) · Obesity Reviews · doi:10.1111/obr.13848 · Cited by 7
“54 Due to unknowable, complicated, and informationally fragmented drug candidates and potential new mechanisms of action, this activity depends on a number of factors, and success is frequently a matter of luck.”
Trends and Applications in Computationally Driven Drug Repurposing
Pinzi, L., & Rastelli, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216511 · Cited by 9
“…for rational drug discovery and repurposing has significantly increased over the last years, along with technological improvements and the availability of public databases [5–7], further advances in medicinal chemistry approaches, and the development of dedicated hardware and software tools [8].”
BackgroundAn overview of current strategies and future prospects in drug repurposing in tuberculosis
Singh, D., Singh, A., & Chawla, P. A. (2023) · Exploration of Medicine · doi:10.37349/emed.2023.00125 · Cited by 7
RetractedLiang, D., Yixuan, D., Liu, C., Jingjing, S., Zhao, S., & Jie, D. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10750-3 · Cited by 7
“Moreover, multiple-database searches may assist in exploring mechanisms and repurposing drugs [31].”
Zheng, L., Zhang, S., Li, Y., Liu, Y., Ge, Q., Gu, L., Xie, Y., Wang, X., Ma, Y., Liu, J., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00817 · Cited by 8
Fuellen, G., & Jünemann, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.912043 · Cited by 5
“However, aggregating genes into gene sets or pathways and checking their enrichment among the over- or underexpressed genes frequently matches existing knowledge and/or can be interpreted in a meaningful way (Tanoli et al., 2021).”
BackgroundKlasifikasi Performa Akademik Siswa Menggunakan Metode Decision Tree dan Naive Bayes
Rahman, A. (2023) · Jurnal SAINTEKOM · doi:10.33020/saintekom.v13i1.349 · Cited by 5
Hermawan, A., Putri, D. D. P., Fatimah, N., Putra, I. M. R., & Lestari, I. A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109809 · Cited by 5
Exploiting Heterogeneous Graphs with GCN for Drug Repositioning
Wu, Z. M., Zainudin, S., & Daud, K. M. (2023) · doi:10.1109/iceei59426.2023.10346720 · Cited by 4
“In terms of mining potential information between known diseases and drugs, the heterogeneous graph data with two types of nodes has already shown promising results in the research methods proposed by current researchers [8].”
ResultChatterjee, A., Khan, R., Mukherjee, T., Sahoo, P. P., Tiwari, L. N., Singh, B. N., Kumari, R., Kumari, A., Rai, A., & Ray, S. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04179-x · Cited by 5
“The use of bioinformatics to develop new drugs and explore the database has opened new areas of opportunities (Law et al. 2020; Tanoli et al. 2020; Xia 2017).”
Integrating bioassay data for improved prediction of drug-target interaction
Dai, W., Li, L., & Guo, D. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106455 · Cited by 4
Modeling ADMET properties based on biomimetic chromatographic data
Vallianatou, T., Tsopelas, F. N., & Tsantili‐Kakoulidou, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18638-7.00004-9 · Cited by 4
Drug repurposing prediction for COVID-19 using probabilistic networks and crowdsourced curationPreprint
Skelton, J., Alsobhe, A., Anastasi, E., Atallah, C., Je, B., Brown, B., Didon, D., Gater, P., James, K., Lennon, D. D., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.11088 · Cited by 4
“Many discoveries are serendipitous, for example from observations in clinics and trials [13].”
BackgroundLi, X., Pan, L., Sanchez‐Burgos, L., Hühn, D., & Fernández-Capetillo, Ó. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.10.532084 · Cited by 4
“Within this module, users can explore for drug-associations to 9 types of diseases ([1] immune-related diseases, [2] syndromes-disorders, [3] degenerative diseases, [4] atrophy/hypertrophy/dystrophy, [5] defects/deficiencies, [6] psychiatric diseases, [8] cancers, [8] infections and [9] other diseases).”
BackgroundMachine Learning and Artificial Intelligence in drug repurposing – challenges and perspectivesPreprint
Anokian, E., Bernett, J., Freeman, A., List, M., Santamaría, L. P., Tanoli, Z., & Bonnin, S. (2024) · doi:10.58647/drugarxiv.pr000007.v1 · Cited by 4
Self-citationMondal, H., Bishal, A., Debnath, B., Patel, A., Das, J., & Taj, T. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00798-2 · Cited by 5
Computational biology approaches for drug repurposing
Waseem, T., Rajput, T. A., Mushtaq, M. S., Babar, M. M., & Rajadas, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.018 · Cited by 4
Drug repositioning by collaborative learning based on graph convolutional inductive network
Teng, Z., Li, Y., Tian, Z., Liang, Y., & Wang, G. (2024) · Future Generation Computer Systems · doi:10.1016/j.future.2024.107491 · Cited by 3
Machine Learning and Artificial Intelligence in drug repurposing – challenges and perspectivesPreprint
Anokian, E., Bernett, J., Freeman, A., List, M., Santamaría, L. P., Tanoli, Z., & Bonnin, S. (2024) · doi:10.58647/drugarxiv.pr000007.v3 · Cited by 3
Self-citationSexton, J. Z. (2022) · The Conversation · doi:10.64628/aai.dftakmwj7 · Cited by 4
Adivarekar, S. S., Udugade, B. V., Biraje, T. M., Palamkar, P. S., Udugade, S., Gaikwad, T. K., M., P. M., & Kandele, S. V. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00437 · Cited by 2
Exploring Artificial Intelligence's Potential to Enhance Conventional Anticancer Drug Development
Bobolea, S., Hinoveanu, M. I., Dimitriu, A., Brașoveanu, M., Iliescu, C., Dinu‐Pîrvu, C., Ghica, M. V., Anuța, V., Popa, L., & Prisada, R. M. (2025) · Drug Development Research · doi:10.1002/ddr.70182 · Cited by 2
“In 2021, Tanoli et al. performed a comprehensive survey on 102 databases supporting drug repurposing, highlighting how these databases can be employed for this endeavor, while providing examples of methods for predicting drug activity by using data from public databases (Tanoli, Seemab et al. 2021).”
DeepTargetClass: a web-based platform for predicting protein target classes of small molecules
Ouassaf, M., & Alhatlani, B. Y. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00717-x · Cited by 2
“In addition, large-scale databases like the Drug Target Commons (DTC) [ 21]and extensive surveys of AI-driven repurposing tools [ 22 ] have provided valuable resources for data-driven drug discovery [ 23].”
Computational studies of target-specific radiopharmaceuticals for theranostics
Gervasoni, S. I., Guccione, C., & Malloci, G. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109264 · Cited by 2
Bianchi, N., Lefebvre, A., Wolstencroft, K., & Spruit, M. R. (2026) · BMC Bioinformatics · doi:10.1186/s12859-026-06376-5 · Cited by 3
“…experimental validation through clinical trial database cross-referencing, pathway-level analyses, and drug-target interaction (DTI) integration [77–81] represents important directions for enhancing biological validation, while systematic comparison against established prediction platforms like…”
Dóra, D., Dóra, T. B., Szegvári, G., Gerdán, C., & Lohinai, Z. (2022) · BioData Mining · doi:10.1186/s13040-022-00307-9 · Cited by 2
“The landscape of cancer research has been transformed by open-access genomic, proteomic databases, such as The Cancer Genome Database (TCGA) [43], Oncomine [32], Human Protein Atlas [44], Cancer Cell Line Encyclopedia [45] or DepMap [46] and a multitude of drug-repurposing databases [3].”
BackgroundFan, S., Yang, K., Lu, K., Xin, D., Li, X., Zhu, Q., Li, S., Zeng, J., & Zhou, X. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae692 · Cited by 2
Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
Perco, P., Ley, M., Kęska, K., Wojenska, D., Bono, E., Walter, S. M., Fillinger, L., & Kratochwill, K. (2025) · PROTEOMICS · doi:10.1002/pmic.202400109 · Cited by 3
Strategies for robust, accurate, and generalizable benchmarking of drug discovery platforms
Norden, M. V., Mangione, W., Falls, Z., & Samudrala, R. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf604 · Cited by 4
“Such static datasets are used instead of or alongside continuously updated databases like Drugbank, the Comparative Toxicogenomics Database (CTD), and Therapeutic Targets Database (TTD) (Wishart et al. 2006, Tanoli et al. 2021a, b, 2025a, Davis et al. 2023, Zhou et al. 2024).”
springD2A: capturing uncertainty in disease–drug association prediction with model integration
Wang, W., Zhang, X.-W., & Dai, D. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab820 · Cited by 2
Gene Signature-Based Drug Repositioning
Jia, Z., Song, X., Shi, J., Wang, W., & He, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.101377 · Cited by 4
BuDb: A Curated Drug Discovery Database for Buruli Ulcer
Kwofie, S. K., Anyimadu, D. T., Aryee, S., Asare, B., Kokroko, N., Owusu, J. A., Afutu, B., Agyapong, O., Mosi, L., Kyei-Baffour, E. S., et al. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416523500011 · Cited by 2
Tools and Data Towards Supporting Quantitative Systems Pharmacology of the Eye – An OverviewPreprint
Kuepfer, L., Fuellen, G., & Stahnke, T. (2022) · Preprints.org · doi:10.20944/preprints202203.0164.v1 · Cited by 2
Metadata
- Authors
- Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M.
- Affiliations
- University of Helsinki (FI)
- University of Copenhagen (DK)
- Corresponding author
- Tanoli, Ziaurrehman
- Tang, Jing
- Vähä-Koskela, Markus
- ORCID
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-14
- Volume
- 22
- Issue
- 2
- Pages
- 1656-1678
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- PMC
- PMC7986597
- OpenAlex
- W3006508031
- Semantic Scholar
- 31b64604c660c457f13b7adb6a3ac7baf643b9f7
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 22 · 2023: 25 · 2022: 25 · 2021: 17 · 2020: 10
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Briefings in Bioinformatics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- European Research Council (716063)
- Academy of Finland (317680)
- European Commission (824087)
- Medicinska Understödsföreningen Liv och Hälsa
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- drug repurposing, drug databases, database selection, molecular targets, drug mechanisms of action, adverse drug reactions, drug discovery
- MeSH terms
- Surveys and Questionnaires, Databases, Factual, Drug Delivery Systems, Computational Biology, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.